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Appendix 1. Medline search strategy
Example of MeSH and key word terms used for the systematic search strategy. The search strategy below was used to conduct the MEDLINE review* 
Appendix 2. Summary of data on network geometry for each network

Recurrent VTE Major Bleeding
Total number of studies 45 42 Total number of studies with 2-arms 43 40 Total number of studies with multiarms 2 2 
Appendix 4. Probability best therapy
We assessed the probability that each treatment was the most efficacious for each outcome by calculating the hazard ratio for each drug compared with LMWH/VKA, and counting the proportion of iterations in which each drug had the most favorable hazard ratio compared with LMWH/VKA. A simple numerical summary of these probabilities -the surface under the cumulative ranking (SUCRA) was calculated. The SUCRA would be 100% when a treatment is certain to be the best and 0% when a treatment is certain to be the worst. SUCRA values enable the ranking of treatments overall for a particular outcome. For example, for recurrent VTE the SUCRA value for LMWH/edoxaban is 72.5%, which is better than other treatments. By contrast, UFH/VKA has a SUCRA of 5.1% for recurrent VTE meaning it is more certain to be worst for this outcome. 
eTable 4b. Surface under the cumulative ranking values (%)
Appendix 5. Proportion of patients experiencing outcomes events
We report the proportion of patients expected to have a recurrent VTE or major bleeding event while using each treatment for a period of 3 and 6 months. These values were calculated, assuming a rate of 5.3 per 100 patient-years (~2.6% over 6 months) and 3.6 events per 100 patient-years (~1.8% over 6 months) for recurrent VTE and major bleeding, respectively, in the LMWH/VKA arm of the Amplify trial. 45;46 The hazard ratios were then applied to this log-rate. 47 Using this value, we calculate the difference in the proportion of patients expected to have an event relative to LMWH/VKA and number needed to treat to benefit (or harm CrI = credible interval; LMWH = low molecular weight heparin; NNTB = number need to treat to benefit; NNTH = number need to treat to harm; UFH = unfractionated heparin; VKA = vitamin K antagonist; VTE = venous thromboembolism *A minus sign (-) indicates that a lower proportion of patients is expected to have an event.
Bold type font indicates significant values.
Appendix 6. Comparison of random-effects bayesian network meta-analysis with direct frequentist meta-analysis estimate for recurrent VTE
The effect estimates from the Bayesian network meta-analysis aligned closely with frequentist pair-wise meta-analyses. There was some heterogeneity within individual comparisons using direct frequentist metaanalysis, particularly for rivaroxaban (I 2 =61%). However, the heterogeneity can be explained by the use of different index events among included studies. There were two rivaroxaban studies and each used a different index event (index DVT and index PE 40;41 ). We stratified recurrent VTE analyses by index event in Figure 3 (main manuscript) to account for this heterogeneity. 1.42 (1.15, 1.80)  1.40 (1.12, 1.77) 
Appendix 7. Sensitivity analysis for duration of study
We present box plots to illustrate the rationale for the sensitivity analyses undertaken to investigate the impact of study duration. The bottom and top of the box in each box plot are the first (Q1) and third (Q3) quartiles, and the band inside the box is the median value. The ends of the whisker are set at 1.5*interquartile range (IQR) above the third quartile (Q3) and 1.5*IQR below the first quartile (Q1), where IQR = Q3 − Q1. If the minimum or maximum values are outside this range, then they are shown as outliers. The small dashes indicate one point is available (Fondaparinux/VKA, LMWH/edoxaban, apixaban) while a long bar indicates two studies with very similar findings (LMWH/dabigatran) and the IQR is not visible unless you zoom in (narrow box plot).
The probability of recurrent VTE is higher in the LMWH/VKA arm of patients using UFH/VKA, Fondaparinux/VKA, and LMWH alone. Probabilities are calculated using the formulas defined by Fluerence et al to convert between probabilities and rates over different time points. 46 This appears partly attributable to the variation in treatment duration, although it is also attributable to combining of index PE and index DVT outcomes in the box plot (which has been stratified in Table 2 and Figure 3 of the manuscript).
eFigure 7a. Box plot comparing treatments in terms of probability of recurrent VTE in LMWH/VKA arm
In general, the studies including direct oral anticoagulants were longer in duration than those for UFH/VKA, Fondaparinux/VKA, LMWH alone (eFigure 7b) resulting in potential variations in the probability of recurrent VTE in the LMWH/VKA arms.
eFigure 7b. Box plot comparing treatments in terms of study treatment duration
We ran the reference case analyses using a Poisson likelihood model. However, we also conducted a subgroup analysis which investigated whether duration of treatment may have impacted results. For this analysis, we restricted studies to those that were 6 months in treatment duration or longer. This resulted in a smaller network (14 studies with 17,053 patient-years of follow-up versus 45 studies with 20,842 patientyears of follow-up). Fondaparinux/VKA was also removed from the network given all studies involving this treatment were less than 6 months in duration. Restriction of the network to studies 6 months in treatment duration or longer resulted in more homogeneous estimates of the probability of recurrent VTE in the LMWH/VKA arm compared to the reference case network (eFigure 7c versus eFigure 7a).
eFigure 7c. Box plot comparing treatments in terms of probability of recurrent VTE in LMWH/VKA arm when restricted to trials with at least 6 months of treatment
The results for the sub-group analysis yielded similar results to the primary analysis, with the exception being that the UFH/VKA effect estimate is slightly higher in the sub-group analysis (1.88 vs 1.42) and LMWH alone is slightly lower (0.79 vs 0.99). These do not change statistical significance from the primary analysis. The relative ordering of the SUCRAs are also similar to the primary analysis. SUCRA values enable the ranking of treatments overall for a particular outcome. The SUCRA would be 100% when a treatment is certain to be the best and 0% when a treatment is certain to be the worst. 
eFigure 8b. Major bleeding. Comparison of Fixed-and Random-Effects models for each treatment versus LMWH/VKA
The model fit statistics for the major bleeding analysis seemed to be better than the recurrent VTE analysis. The between study standard deviation was lower (0.139 vs 0.202) and the total residual deviance was closer to the number of unconstrained data points (even if we exclude the double/multiple zero cells). Accordingly, we conducted numerous sensitivity analyses related to recurrent VTE. In particular, we conducted an analysis where we stratify by index PE/DVT ( Figure 3 and Table 2 of manuscript). We also conducted an analysis where we only considered studies 6 months or longer treatment duration (Appendix 7) and another analysis removing studies that did not fit the model well (Appendix 10). The results for the latter 2 analyses did not alter findings substantially, while there were some differences when results were stratified by index event. 
